tokai pharmaceuticals inc
(TKAI:Consolidated Issue listed on NASDAQ Global Market)
Philip W. Kantoff M.D.
Chief Clinical Research Officer and Member of Medical Advisory Committee, Tokai Pharmaceuticals, Inc.
|Age||Total Calculated Compensation||This person is connected to 76 board members in 6 different organizations across 7 different industries.|
See Board Relationships
Dr. Philip W. Kantoff, M.D. serves as Scientific & Clinical Advisor at Metamark Genetics, Inc. Dr. Kantoff serves as Chief Clinical Research Officer of Tokai Pharmaceuticals, Inc. He has been Chief Clinical Research Officer at Dana-Farber Cancer Institute, Inc. since October 2006. He serves as Chief of Division of Solid Tumor Oncology and Leader of the Dana-Farber and Harvard Cancer Center Prostate Cancer Program. He joined Dana-Farber in 1987. Mr. Kantoff serves as ...
One BroadwayPhone: 617-225-4305
Cambridge, Massachusetts 02142
Board Members Memberships*There is no Board Members Memberships data available.
Unknown/Other Education 1979
Brown University Medical School
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|There is no Competitor Compensation data available.|